How does montelukast (Singulair), a leukotriene blocker, work in the treatment of asthma?

Choice A reason: Montelukast does not increase vessel permeability. It blocks the effects of leukotrienes, which are inflammatory mediators that cause vessel permeability, bronchoconstriction, and mucus secretion. By blocking leukotrienes, montelukast reduces vessel permeability and inflammation. Choice B reason: Montelukast reduces bronchoconstriction and mucus secretion. It blocks the effects of leukotrienes, which are inflammatory mediators that cause bronchoconstriction and mucus secretion. By blocking leukotrienes, montelukast improves airflow and reduces asthma symptoms. Choice C reason: Montelukast does not increase inflammation. It blocks the effects of leukotrienes, which are inflammatory mediators that cause inflammation, bronchoconstriction, and mucus secretion. By blocking leukotrienes, montelukast reduces inflammation and prevents asthma exacerbations. Choice D reason: Montelukast does not increase bronchoconstriction. It blocks the effects of leukotrienes, which are inflammatory mediators that cause bronchoconstriction, mucus secretion, and inflammation. By blocking leukotrienes, montelukast reduces bronchoconstriction and improves airflow.